JP2019151627A5 - - Google Patents

Download PDF

Info

Publication number
JP2019151627A5
JP2019151627A5 JP2019035140A JP2019035140A JP2019151627A5 JP 2019151627 A5 JP2019151627 A5 JP 2019151627A5 JP 2019035140 A JP2019035140 A JP 2019035140A JP 2019035140 A JP2019035140 A JP 2019035140A JP 2019151627 A5 JP2019151627 A5 JP 2019151627A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
diabetes
acceptable salt
compound according
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019035140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019151627A (ja
JP7206132B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019151627A publication Critical patent/JP2019151627A/ja
Publication of JP2019151627A5 publication Critical patent/JP2019151627A5/ja
Priority to JP2023000037A priority Critical patent/JP2023026566A/ja
Application granted granted Critical
Publication of JP7206132B2 publication Critical patent/JP7206132B2/ja
Priority to JP2024214451A priority patent/JP2025026615A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019035140A 2018-03-01 2019-02-28 メチルラクタム環化合物及びその医薬用途 Active JP7206132B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023000037A JP2023026566A (ja) 2018-03-01 2023-01-04 メチルラクタム環化合物及びその医薬用途
JP2024214451A JP2025026615A (ja) 2018-03-01 2024-12-09 メチルラクタム環化合物及びその医薬用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018036307 2018-03-01
JP2018036307 2018-03-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023000037A Division JP2023026566A (ja) 2018-03-01 2023-01-04 メチルラクタム環化合物及びその医薬用途

Publications (3)

Publication Number Publication Date
JP2019151627A JP2019151627A (ja) 2019-09-12
JP2019151627A5 true JP2019151627A5 (cg-RX-API-DMAC7.html) 2022-03-07
JP7206132B2 JP7206132B2 (ja) 2023-01-17

Family

ID=67806229

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019035140A Active JP7206132B2 (ja) 2018-03-01 2019-02-28 メチルラクタム環化合物及びその医薬用途
JP2023000037A Pending JP2023026566A (ja) 2018-03-01 2023-01-04 メチルラクタム環化合物及びその医薬用途
JP2024214451A Pending JP2025026615A (ja) 2018-03-01 2024-12-09 メチルラクタム環化合物及びその医薬用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023000037A Pending JP2023026566A (ja) 2018-03-01 2023-01-04 メチルラクタム環化合物及びその医薬用途
JP2024214451A Pending JP2025026615A (ja) 2018-03-01 2024-12-09 メチルラクタム環化合物及びその医薬用途

Country Status (21)

Country Link
US (4) US11014910B2 (cg-RX-API-DMAC7.html)
EP (1) EP3760624A4 (cg-RX-API-DMAC7.html)
JP (3) JP7206132B2 (cg-RX-API-DMAC7.html)
KR (1) KR102795351B1 (cg-RX-API-DMAC7.html)
CN (1) CN111757877B (cg-RX-API-DMAC7.html)
AR (1) AR114418A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019227770B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016788A2 (cg-RX-API-DMAC7.html)
CA (1) CA3087859A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002199A1 (cg-RX-API-DMAC7.html)
IL (1) IL276311B2 (cg-RX-API-DMAC7.html)
MA (1) MA52427A (cg-RX-API-DMAC7.html)
MX (1) MX2020009070A (cg-RX-API-DMAC7.html)
MY (1) MY205197A (cg-RX-API-DMAC7.html)
PE (1) PE20210123A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551340A1 (cg-RX-API-DMAC7.html)
SA (1) SA520420037B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007120UA (cg-RX-API-DMAC7.html)
TW (1) TWI805699B (cg-RX-API-DMAC7.html)
WO (1) WO2019168096A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202004600B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
TWI805727B (zh) 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途
CN114585387B (zh) * 2019-09-04 2024-10-29 日本烟草产业株式会社 利用联用药物的糖尿病的治疗或预防方法
CN114641314B (zh) * 2019-09-04 2024-05-28 日本烟草产业株式会社 慢性肾脏病的治疗或预防方法
EP4122495A4 (en) * 2020-03-19 2024-03-27 Japan Tobacco Inc. Treatment or prevention method for chronic heart failure

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
RU2332412C2 (ru) 2003-02-07 2008-08-27 Дайити Фармасьютикал Ко., Лтд. Производные пиразола
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
DE602005017895D1 (de) 2004-07-07 2010-01-07 Merck & Co Inc Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4137956B2 (ja) * 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
KR100970294B1 (ko) 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
CN101243074A (zh) * 2005-06-08 2008-08-13 日本烟草产业株式会社 杂环化合物
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
EP1991528A2 (en) 2006-01-18 2008-11-19 Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
CA2650566A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
EP2064222B1 (en) * 2007-04-02 2014-05-07 Theracos, Inc. Benzylic glycoside derivatives and methods of use
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
BR112018016671A2 (pt) * 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
TWI805727B (zh) 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途

Similar Documents

Publication Publication Date Title
JP2019048894A5 (cg-RX-API-DMAC7.html)
JP2020097577A5 (cg-RX-API-DMAC7.html)
JP2021191784A5 (cg-RX-API-DMAC7.html)
JP2024516371A5 (cg-RX-API-DMAC7.html)
JP2013032389A5 (cg-RX-API-DMAC7.html)
JP2013518107A5 (cg-RX-API-DMAC7.html)
JP2015078230A5 (cg-RX-API-DMAC7.html)
JP2012255026A5 (cg-RX-API-DMAC7.html)
CN110248926A (zh) Lsd1抑制剂及其制备方法和应用
JP2017105793A5 (cg-RX-API-DMAC7.html)
JP2011518833A5 (cg-RX-API-DMAC7.html)
JP2011527299A5 (cg-RX-API-DMAC7.html)
JP2017537066A5 (cg-RX-API-DMAC7.html)
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
JP2015024998A5 (cg-RX-API-DMAC7.html)
JP2006526031A5 (cg-RX-API-DMAC7.html)
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
JP2016518337A5 (cg-RX-API-DMAC7.html)
JP2013542247A5 (cg-RX-API-DMAC7.html)
JP2017506627A5 (cg-RX-API-DMAC7.html)
JP2014530818A5 (cg-RX-API-DMAC7.html)
EP4663637A3 (en) Novel deuterium substituted positron emission tomography (pet) imaging agents and their pharmacological application
JP2014500861A5 (cg-RX-API-DMAC7.html)
JP2017517565A5 (cg-RX-API-DMAC7.html)
JP2018145180A5 (cg-RX-API-DMAC7.html)